Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden

In non-small-cell lung cancer (NSCLC) refractory to standard therapy and which lacks well-known oncogenic drivers, genomic profiling can still identify genomic alterations that may suggest potential sensitivity to targeted therapy. PTEN mutation in NSCLC may be sensitizing to analogs of rapamycin su...

Descripción completa

Detalles Bibliográficos
Autores principales: Parikh, Ankur R, Ali, Siraj M, Schrock, Alexa B, Albacker, Lee A, Miller, Vincent A, Stephens, Phil J, Crilley, Pamela, Markman, Maurie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963481/
https://www.ncbi.nlm.nih.gov/pubmed/29844707
http://dx.doi.org/10.2147/LCTT.S161738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963481/
https://www.ncbi.nlm.nih.gov/pubmed/29844707
http://dx.doi.org/10.2147/LCTT.S161738

Ejemplares similares